CRISPR Therapeutics (CRSP) Upgraded by ValuEngine to “Hold”

ValuEngine upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP) from a sell rating to a hold rating in a report released on Monday.

Other equities analysts also recently issued research reports about the company. SunTrust Banks reiterated a buy rating and issued a $65.00 price objective on shares of CRISPR Therapeutics in a report on Friday, March 9th. Piper Jaffray reiterated a buy rating and issued a $22.75 price objective (down previously from $39.00) on shares of CRISPR Therapeutics in a report on Wednesday, January 10th. BidaskClub upgraded CRISPR Therapeutics from a hold rating to a buy rating in a report on Thursday, January 4th. TheStreet upgraded CRISPR Therapeutics from a d+ rating to a c rating in a report on Friday, March 16th. Finally, Oppenheimer reiterated a hold rating on shares of CRISPR Therapeutics in a report on Thursday, December 21st. Five equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $63.95.

How to Become a New Pot Stock Millionaire

CRSP traded up $3.77 during trading on Monday, reaching $46.44. The stock had a trading volume of 1,202,698 shares, compared to its average volume of 1,095,946. The company has a market cap of $2,082.42, a price-to-earnings ratio of -24.95 and a beta of 3.56. CRISPR Therapeutics has a one year low of $13.50 and a one year high of $61.24.

In other news, insider Tyler Dylan-Hyde sold 66,000 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $28.03, for a total transaction of $1,849,980.00. Following the completion of the transaction, the insider now directly owns 25,204 shares in the company, valued at $706,468.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 39.98% of the stock is owned by company insiders.

Several large investors have recently modified their holdings of the company. Wells Fargo & Company MN increased its holdings in shares of CRISPR Therapeutics by 17.2% during the fourth quarter. Wells Fargo & Company MN now owns 21,517 shares of the company’s stock valued at $505,000 after acquiring an additional 3,165 shares in the last quarter. ARK Investment Management LLC increased its holdings in shares of CRISPR Therapeutics by 22.8% during the fourth quarter. ARK Investment Management LLC now owns 31,388 shares of the company’s stock valued at $737,000 after acquiring an additional 5,833 shares in the last quarter. Creative Planning bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at $243,000. Paloma Partners Management Co bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at $290,000. Finally, D.A. Davidson & CO. bought a new position in shares of CRISPR Therapeutics during the fourth quarter valued at $370,000. Hedge funds and other institutional investors own 26.61% of the company’s stock.

WARNING: “CRISPR Therapeutics (CRSP) Upgraded by ValuEngine to “Hold”” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3335519/crispr-therapeutics-crsp-upgraded-by-valuengine-to-hold.html.

About CRISPR Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Texas Capital Bancshares  Upgraded to Overweight at Piper Jaffray
Texas Capital Bancshares Upgraded to Overweight at Piper Jaffray
DA Davidson Research Analysts Lift Earnings Estimates for Comerica Inc
DA Davidson Research Analysts Lift Earnings Estimates for Comerica Inc
Jefferies Group Weighs in on Nikon’s FY2019 Earnings
Jefferies Group Weighs in on Nikon’s FY2019 Earnings
Jeffrey R. Hines Acquires 557 Shares of The York Water Company  Stock
Jeffrey R. Hines Acquires 557 Shares of The York Water Company Stock
Motorcar Parts of America Inc.  Given Consensus Recommendation of “Hold” by Brokerages
Motorcar Parts of America Inc. Given Consensus Recommendation of “Hold” by Brokerages
Casa Systems  Receives Average Rating of “Buy” from Analysts
Casa Systems Receives Average Rating of “Buy” from Analysts


Leave a Reply

© 2006-2018 Ticker Report. Google+.